# | Title | Journal | Year | Citations |
---|
1 | Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence | Clinical Cancer Research | 2007 | 3,807 |
2 | X-Tile | Clinical Cancer Research | 2004 | 2,925 |
3 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria | Clinical Cancer Research | 2009 | 2,857 |
4 | Therapeutic Nanoparticles for Drug Delivery in Cancer | Clinical Cancer Research | 2008 | 2,565 |
5 | Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma | Clinical Cancer Research | 2004 | 2,393 |
6 | Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases | Clinical Cancer Research | 2004 | 2,261 |
7 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers | Clinical Cancer Research | 2013 | 2,097 |
8 | Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy | Clinical Cancer Research | 2014 | 2,050 |
9 | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer | Clinical Cancer Research | 2008 | 1,975 |
10 | Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity | Clinical Cancer Research | 2006 | 1,895 |
11 | Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy | Clinical Cancer Research | 2011 | 1,823 |
12 | The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes | Clinical Cancer Research | 2007 | 1,786 |
13 | The Interleukin-8 Pathway in Cancer | Clinical Cancer Research | 2008 | 1,747 |
14 | Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy | Clinical Cancer Research | 2005 | 1,618 |
15 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship | Clinical Cancer Research | 2003 | 1,474 |
16 | Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody | Clinical Cancer Research | 2009 | 1,371 |
17 | Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome | Clinical Cancer Research | 2008 | 1,312 |
18 | Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System | Clinical Cancer Research | 2007 | 1,204 |
19 | The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research | Clinical Cancer Research | 2009 | 1,177 |
20 | CXCL12 (SDF-1)/CXCR4 Pathway in Cancer | Clinical Cancer Research | 2010 | 1,159 |
21 | Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer | Clinical Cancer Research | 2008 | 1,158 |
22 | Phase I Clinical Trial of Oral Curcumin | Clinical Cancer Research | 2004 | 1,097 |
23 | The Pancreas Cancer Microenvironment | Clinical Cancer Research | 2012 | 1,087 |
24 | Prostate-specific membrane antigen expression in normal and malignant human tissues | Clinical Cancer Research | 1997 | 1,056 |
25 | A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer | Clinical Cancer Research | 2006 | 1,050 |
26 | Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype | Clinical Cancer Research | 2008 | 1,040 |
27 | Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. | Clinical Cancer Research | 2006 | 1,025 |
28 | Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate | Clinical Cancer Research | 2004 | 1,019 |
29 | Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer | Clinical Cancer Research | 2012 | 1,018 |
30 | Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide | Clinical Cancer Research | 2004 | 1,014 |
31 | Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma | Clinical Cancer Research | 2014 | 1,012 |
32 | Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma | Clinical Cancer Research | 2007 | 1,005 |
33 | Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer | Clinical Cancer Research | 2015 | 990 |
34 | EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis | Clinical Cancer Research | 2016 | 977 |
35 | The Double-Edged Sword of Autophagy Modulation in Cancer | Clinical Cancer Research | 2009 | 965 |
36 | Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 | Clinical Cancer Research | 2017 | 960 |
37 | Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival | Clinical Cancer Research | 2006 | 937 |
38 | Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity | Clinical Cancer Research | 2005 | 923 |
39 | EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer | Clinical Cancer Research | 2008 | 916 |
40 | Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects | Clinical Cancer Research | 2005 | 882 |
41 | Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy | Clinical Cancer Research | 2009 | 875 |
42 | Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment | Clinical Cancer Research | 2009 | 872 |
43 | Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? | Clinical Cancer Research | 2012 | 855 |
44 | An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance | Clinical Cancer Research | 2013 | 848 |
45 | Circulating Tumor Cells in Patients with Breast Cancer Dormancy | Clinical Cancer Research | 2004 | 846 |
46 | Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series | Clinical Cancer Research | 2007 | 839 |
47 | Reactive Oxygen Species: A Breath of Life or Death?: Fig. 1. | Clinical Cancer Research | 2007 | 837 |
48 | BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma | Clinical Cancer Research | 2013 | 832 |
49 | The Definition of Primary and Secondary Glioblastoma | Clinical Cancer Research | 2013 | 819 |
50 | Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer | Clinical Cancer Research | 2005 | 819 |